Downregulation of ITIH3 contributes to cisplatin‑based chemotherapy resistance in ovarian carcinoma via the Bcl‑2 mediated anti‑apoptosis signaling pathway

Liu,Yingzhao; Shi,Lijun; Yuan,Cunzhong; Feng,Yan; Li,Mengdi; Liu,Hongmei; Chen,Xi; Yao,Desheng; Wang,Qi

doi:10.3892/ol.2022.13646

Downregulation of ITIH3 contributes to cisplatin‑based chemotherapy resistance in ovarian carcinoma via the Bcl‑2 mediated anti‑apoptosis signaling pathway

Authors:
- Yingzhao Liu
- Lijun Shi
- Cunzhong Yuan
- Yan Feng
- Mengdi Li
- Hongmei Liu
- Xi Chen
- Desheng Yao
- Qi Wang
View Affiliations

Affiliations: Department of Gynecologic Oncology, Guangxi Medical University Affiliated Tumor Hospital, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China, Department of Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China, Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China, Research Department, Guangxi Medical University Affiliated Tumor Hospital, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China, Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor, Guangxi Medical University, Ministry of Education, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China
Published online on: December 21, 2022 https://doi.org/10.3892/ol.2022.13646
Article Number: 61
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Platinum resistance of ovarian cancer is one of the primary factors of poor prognosis and inter‑α‑trypsin inhibitor heavy chain 3 (ITIH3) is a potential DDP resistance‑associated gene. The present study assessed protein expression levels of ITIH3 in human ovarian cancer and evaluated the relationship between its expression and platinum‑resistance in patients. Furthermore, the effect of ITIH3 on cisplatin (DDP)‑resistant ovarian cancer cells and the underlying molecular mechanism were evaluated. Tissue microarrays of ovarian cancer samples were used to assess the association between ITIH3 protein expression levels and drug resistance and the prognosis of ovarian cancer. ITIH3 RNA interference (RNAi) ovarian cancer cell lines were constructed and expression levels of anti‑ and pro‑apoptotic proteins of the Bcl‑2 associated pathway, including Bcl‑2, Bcl‑xL, Mcl‑1, Bak, Bim, Bax, caspase 3 and poly ADP‑ribose polymerase (PARP), were assessed following DDP treatment. The Bcl‑2 inhibitor ABT‑737 was used to rescue DDP‑resistance induced by loss of ITIH3 in vitro. Finally, a subcutaneous xenograft tumor model was used to evaluate the effect of multiple DDP injections on expression levels of apoptosis‑related proteins like Bcl‑2, Bcl‑xL, Bak, caspase 3 and PARP. The results of tissue microarray immunohistochemistry revealed that decreased ITIH3 protein expression levels were associated with a shorter overall survival for patients with ovarian cancer. The results of Cell Counting Kit‑8 assay showed that the half‑maximal inhibitory concentration and resistance index of DDP in SKOV3‑ITIH3 and OVCAR3‑ITIH3 RNAi cells were significantly higher than in control groups. Following DDP treatment, the results of western blotting revealed that expression levels of anti‑apoptotic proteins of the Bcl‑2 family significantly increased in SKOV3‑ITIH3 and OVCAR3‑ITIH3 RNAi cells. Pro‑apoptotic protein expression was not significantly changed following DDP treatment, whereas cleaved caspase 3, caspase 3 and cleaved (C‑PARP) were markedly downregulated. The Bcl‑2 inhibitor ABT‑737 was demonstrated to reverse increased DDP resistance induced by ITIH3 expression in flow cytometric and western blotting analysis. In the subcutaneous murine xenograft model, an increased number of DDP injections yielded a decrease in phosphorylated Bcl‑2, cleaved caspase 3, caspase 3 and C‑PARP protein expression levels in the SKOV3‑ITIH3 RNAi group tested by western blotting. To the best of our knowledge, this is the first study to demonstrate that ITIH3 could be a vital molecule involved in chemosensitivity via regulation of the Bcl‑2 family‑mediated apoptotic pathway. Lower protein expression levels of ITIH3 were significantly associated with platinum resistance and poor prognosis in ovarian cancer. ITIH3 may predict cisplatin‑resistance in ovarian cancer.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
2	Rottenberg S, Disler C and Perego P: The rediscovery of platinum-based cancer therapy. Nat Rev Cancer. 21:37–50. 2021. View Article : Google Scholar : PubMed/NCBI
3	Kuroki L and Guntupalli SR: Treatment of epithelial ovarian cancer. BMJ. 371:m37732020. View Article : Google Scholar : PubMed/NCBI
4	Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J and Karlan BY: Ovarian cancer. Nat Rev Dis Primers. 2:160612016. View Article : Google Scholar : PubMed/NCBI
5	Shi L, Yu H, Zhang W, Li L and Wang Q: Establishment and biological characteristics of a platinum-resistance nude mouse model in epithelial ovarian cancer. Zhonghua Fu Chan Ke Za Zhi. 49:523–530. 2014.(In Chinese). PubMed/NCBI
6	Bost F, Diarra-Mehrpour M and Martin JP: Inter-alpha-trypsin inhibitor proteoglycan family-a group of proteins binding and stabilizing the extracellular matrix. Eur J Biochem. 252:339–346. 1998. View Article : Google Scholar : PubMed/NCBI
7	Zhuo L, Hascall VC and Kimata K: Inter-alpha-trypsin inhibitor, a covalent protein-glycosaminoglycan-protein complex. J Biol Chem. 279:38079–38082. 2004. View Article : Google Scholar : PubMed/NCBI
8	Hamm A, Veeck J, Bektas N, Wild PJ, Hartmann A, Heindrichs U, Kristiansen G, Werbowetski-Ogilvie T, Del Maestro R, Knuechel R and Dahl E: Frequent expression loss of Inter-alpha-trypsin inhibitor heavy chain (ITIH) genes in multiple human solid tumors: A systematic expression analysis. BMC Cancer. 8:252008. View Article : Google Scholar : PubMed/NCBI
9	Kopylov AT, Stepanov AA, Malsagova KA, Soni D, Kushlinsky NE, Enikeev DV, Potoldykova NV, Lisitsa AV and Kaysheva AL: Revelation of proteomic indicators for colorectal cancer in initial stages of development. Molecules. 25:6192020. View Article : Google Scholar : PubMed/NCBI
10	Liu X, Zheng W, Wang W, Shen H, Liu L, Lou W, Wang X and Yang P: A new panel of pancreatic cancer biomarkers discovered using a mass spectrometry-based pipeline. Br J Cancer. 118:e152018. View Article : Google Scholar : PubMed/NCBI
11	Peng H, Pan S, Yan Y, Brand RE, Petersen GM, Chari ST, Lai LA, Eng JK, Brentnall TA and Chen R: Systemic proteome alterations linked to early stage pancreatic cancer in diabetic patients. Cancers (Basel). 12:15342020. View Article : Google Scholar : PubMed/NCBI
12	Chong PK, Lee H, Zhou J, Liu SC, Loh MC, Wang TT, Chan SP, Smoot DT, Ashktorab H, So JB, et al: ITIH3 is a potential biomarker for early detection of gastric cancer. J Proteome Res. 9:3671–3679. 2010. View Article : Google Scholar : PubMed/NCBI
13	Dufresne J, Bowden P, Thavarajah T, Florentinus-Mefailoski A, Chen ZZ, Tucholska M, Norzin T, Ho MT, Phan M, Mohamed N, et al: The plasma peptides of breast versus ovarian cancer. Clin Proteomics. 16:432019. View Article : Google Scholar : PubMed/NCBI
14	Ivancic MM, Huttlin EL, Chen X, Pleiman JK, Irving AA, Hegeman AD, Dove WF and Sussman MR: Candidate serum biomarkers for early intestinal cancer using 15N metabolic labeling and quantitative proteomics in the ApcMin/+ mouse. J Proteome Res. 12:4152–4166. 2013. View Article : Google Scholar : PubMed/NCBI
15	Thavarajah T, Dos Santos CC, Slutsky AS, Marshall JC, Bowden P, Romaschin A and Marshall JG: The plasma peptides of sepsis. Clin Proteomics. 17:262020. View Article : Google Scholar : PubMed/NCBI
16	Feng Y, Tang Y, Mao Y, Liu Y, Yao D, Yang L, Garson K, Vanderhyden BC and Wang Q: PAX2 promotes epithelial ovarian cancer progression involving fatty acid metabolic reprogramming. Int J Oncol. 56:697–708. 2020.PubMed/NCBI
17	Dongol S, Zhang Q, Qiu C, Sun C, Zhang Z, Wu H and Kong B: IQGAP3 promotes cancer proliferation and metastasis in high-grade serous ovarian cancer. Oncol Lett. 20:1179–1192. 2020. View Article : Google Scholar : PubMed/NCBI
18	Wu H, Li R, Zhang Z, Jiang H, Ma H, Yuan C, Sun C, Li Y and Kong B: Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer. J Ovarian Res. 12:1252019. View Article : Google Scholar : PubMed/NCBI
19	Meng Q, Duan P, Li L and Miao Y: Expression of placenta growth factor is associated with unfavorable prognosis of advanced-stage serous ovarian cancer. Tohoku J Exp Med. 244:291–296. 2018. View Article : Google Scholar : PubMed/NCBI
20	Zhang R, Hao J, Wu Q, Guo K, Wang C, Zhang WK, Liu W, Wang Q and Yang X: Dehydrocostus lactone inhibits cell proliferation and induces apoptosis by PI3K/Akt/Bad and ERS signalling pathway in human laryngeal carcinoma. J Cell Mol Med. 24:6028–6042. 2020. View Article : Google Scholar : PubMed/NCBI
21	Wang Q, Tang Y, Yu H, Yin Q, Li M, Shi L, Zhang W, Li D and Li L: CCL18 from tumor-cells promotes epithelial ovarian cancer metastasis via mTOR signaling pathway. Mol Carcinog. 55:1688–1699. 2016. View Article : Google Scholar : PubMed/NCBI
22	Kilkenny C, Browne WJ, Cuthill IC, Emerson M and Altman DG: Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research. PLoS Biol. 8:e10004122010. View Article : Google Scholar : PubMed/NCBI
23	Chen F, Sun F, Liu X, Shao J and Zhang B: Glaucocalyxin A inhibits the malignant progression of epithelial ovarian cancer by affecting the MicroRNA-374b-5p/HMGB3/Wnt-β-catenin pathway axis. Front Oncol. 12:9558302022. View Article : Google Scholar : PubMed/NCBI
24	Wang Z, Jensen MA and Zenklusen JC: A Practical guide to the cancer genome atlas (TCGA). Methods Mol Biol. 1418:111–141. 2016. View Article : Google Scholar : PubMed/NCBI
25	Jiang X, Bai XY, Li B, Li Y, Xia K, Wang M, Li S and Wu H: Plasma inter-alpha-trypsin inhibitor heavy chains H3 and H4 serve as novel diagnostic biomarkers in human colorectal cancer. Dis Markers. 2019:50696142019. View Article : Google Scholar : PubMed/NCBI
26	Wijdeven RH, Pang B, Assaraf YG and Neefjes J: Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics. Drug Resist Updat. 28:65–81. 2016. View Article : Google Scholar : PubMed/NCBI
27	Wlodkowic D, Telford W, Skommer J and Darzynkiewicz Z: Apoptosis and beyond: Cytometry in studies of programmed cell death. Methods Cell Biol. 103:55–98. 2011. View Article : Google Scholar : PubMed/NCBI
28	Martinou JC and Youle RJ: Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics. Dev Cell. 21:92–101. 2011. View Article : Google Scholar : PubMed/NCBI
29	Youle RJ and Strasser A: The BCL-2 protein family: Opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 9:47–59. 2008. View Article : Google Scholar : PubMed/NCBI
30	Singh R, Letai A and Sarosiek K: Regulation of apoptosis in health and disease: The balancing act of BCL-2 family proteins. Nat Rev Mol Cell Biol. 20:175–193. 2019. View Article : Google Scholar : PubMed/NCBI
31	Maundrell K, Antonsson B, Magnenat E, Camps M, Muda M, Chabert C, Gillieron C, Boschert U, Vial-Knecht E, Martinou JC and Arkinstall S: Bcl-2 undergoes phosphorylation by c-Jun N-terminal kinase/stress-activated protein kinases in the presence of the constitutively active GTP-binding protein Rac1. J Biol Chem. 272:25238–25242. 1997. View Article : Google Scholar : PubMed/NCBI
32	Yamamoto K, Ichijo H and Korsmeyer SJ: BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol Cell Biol. 19:8469–8478. 1999. View Article : Google Scholar : PubMed/NCBI
33	Huang ST and Cidlowski JA: Phosphorylation status modulates Bcl-2 function during glucocorticoid-induced apoptosis in T lymphocytes. FASEB J. 16:825–832. 2002. View Article : Google Scholar : PubMed/NCBI
34	Ebana Y, Ozaki K, Inoue K, Sato H, Iida A, Lwin H, Saito S, Mizuno H, Takahashi A, Nakamura T, et al: A functional SNP in ITIH3 is associated with susceptibility to myocardial infarction. J Hum Genet. 52:220–229. 2007. View Article : Google Scholar : PubMed/NCBI
35	Xie X, Meng H, Wu H, Hou F, Chen Y, Zhou Y, Xue Q, Zhang J, Gong J, Li L and Song R: Integrative analyses indicate an association between ITIH3 polymorphisms with autism spectrum disorder. Sci Rep. 10:52232020. View Article : Google Scholar : PubMed/NCBI
36	Li K, Li Y, Wang J, Huo Y, Huang D, Li S, Liu J, Li X, Liu R, Chen X, et al: A functional missense variant in ITIH3 affects protein expression and neurodevelopment and confers schizophrenia risk in the Han Chinese population. J Genet Genomics. 47:233–248. 2020. View Article : Google Scholar : PubMed/NCBI
37	Liao CC, Chou PL, Cheng CW, Chang YS, Chi WM, Tsai KL, Chen WJ, Kung TS, Tai CC, Lee KW, et al: Comparative analysis of novel autoantibody isotypes against citrullinated-inter-alpha-trypsin inhibitor heavy chain 3 (ITIH3)(542–556) peptide in serum from Taiwanese females with rheumatoid arthritis, primary Sjögren's syndrome and secondary Sjögren's syndrome in rheumatoid arthritis. J Proteomics. 141:1–11. 2016. View Article : Google Scholar : PubMed/NCBI
38	Cuvelier A, Muir JF, Martin JP and Sesboüé R: Proteins of the inter-alpha trypsin inhibitor (ITI) family. A major role in the biology of the extracellular matrix. Rev Mal Respir. 17:437–446. 2000.(In French). PubMed/NCBI
39	Zhuo L and Kimata K: Structure and function of inter-alpha-trypsin inhibitor heavy chains. Connect Tissue Res. 49:311–320. 2008. View Article : Google Scholar : PubMed/NCBI
40	Hennies HC: All is balanced: Inter-α-trypsin inhibitors as unseen extracellular matrix proteins in epidermal morphology and differentiation. Exp Dermatol. 24:661–662. 2015. View Article : Google Scholar : PubMed/NCBI